<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1154" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1154/" /><meta name="ncbi_pagename" content="Ataxia with Oculomotor Apraxia Type 2 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ataxia with Oculomotor Apraxia Type 2 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Ataxia with Oculomotor Apraxia Type 2" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/07/12" /><meta name="citation_author" content="Maria-Ceu Moreira" /><meta name="citation_author" content="Michel Koenig" /><meta name="citation_pmid" content="20301333" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1154/" /><meta name="citation_keywords" content="AOA2" /><meta name="citation_keywords" content="AOA2" /><meta name="citation_keywords" content="Probable helicase senataxin" /><meta name="citation_keywords" content="SETX" /><meta name="citation_keywords" content="Ataxia with Oculomotor Apraxia Type 2" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ataxia with Oculomotor Apraxia Type 2" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Maria-Ceu Moreira" /><meta name="DC.Contributor" content="Michel Koenig" /><meta name="DC.Date" content="2018/07/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1154/" /><meta name="description" content="Ataxia with oculomotor apraxia type 2 (AOA2) is characterized by onset of ataxia between age three and 30 years after initial normal development, axonal sensorimotor neuropathy, oculomotor apraxia, cerebellar atrophy, and elevated serum concentration of alpha-fetoprotein (AFP)." /><meta name="og:title" content="Ataxia with Oculomotor Apraxia Type 2" /><meta name="og:type" content="book" /><meta name="og:description" content="Ataxia with oculomotor apraxia type 2 (AOA2) is characterized by onset of ataxia between age three and 30 years after initial normal development, axonal sensorimotor neuropathy, oculomotor apraxia, cerebellar atrophy, and elevated serum concentration of alpha-fetoprotein (AFP)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1154/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/aoa2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1154/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D429EE041106100000000015B008A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1154_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1154_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aoa/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/aved/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1154_"><span class="title" itemprop="name">Ataxia with Oculomotor Apraxia Type 2</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: AOA2</div><p class="contrib-group"><span itemprop="author">Maria-Ceu Moreira</span>, MSc, PhD and <span itemprop="author">Michel Koenig</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1154_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1154_ai__"><div class="contrib half_rhythm"><span itemprop="author">Maria-Ceu Moreira</span>, MSc, PhD<div class="affiliation small">Professor of Molecular Biology and Genetics<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.liamtoh@smuecm" class="oemail">rf.liamtoh@smuecm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michel Koenig</span>, MD, PhD<div class="affiliation small">Laboratoire de G&#x000e9;n&#x000e9;tique de Maladies Rares<br />Institut Universitaire de Recherche Clinique<br />Universit&#x000e9; de Montpellier<br />Montpellier, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.mresni@gineok.lehcim" class="oemail">rf.mresni@gineok.lehcim</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 15, 2004</span>; Last Update: <span itemprop="dateModified">July 12, 2018</span>.</p><p><em>Estimated reading time: 19 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="aoa2.Summary" itemprop="description"><h2 id="_aoa2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Ataxia with oculomotor apraxia type 2 (AOA2) is characterized by onset of ataxia between age three and 30 years after initial normal development, axonal sensorimotor neuropathy, oculomotor apraxia, cerebellar atrophy, and elevated serum concentration of alpha-fetoprotein (AFP).</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of AOA2 is based on clinical, laboratory, and radiographic features; family history; and exclusion of the diagnosis of ataxia-telangiectasia, AOA1, and AOA4. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SETX</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> confirms the diagnosis.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Physical therapy for disabilities resulting from peripheral neuropathy; wheelchair for mobility as needed; educational support (e.g., computer with speech recognition and special keyboard for typing) to compensate for difficulties in reading (caused by oculomotor apraxia) and in writing (caused by upper-limb ataxia).</p><p><i>Preventions of secondary complications:</i> A low-cholesterol diet is advised.</p><p><i>Surveillance:</i> Routine follow up with a neurologist.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>AOA2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p></div></div><div id="aoa2.Diagnosis"><h2 id="_aoa2_Diagnosis_">Diagnosis</h2><div id="aoa2.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Ataxia with oculomotor apraxia type 2 (AOA2) <b>should be suspected</b> in individuals with the following clinical, laboratory, and radiographic features.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Cerebellar ataxia</div></li><li class="half_rhythm"><div>Absent or diminished tendon reflexes and later a peripheral axonal sensorimotor neuropathy (&#x0003e;90% of individuals)</div></li><li class="half_rhythm"><div>Oculomotor apraxia (~51% of individuals)</div></li><li class="half_rhythm"><div>Pyramidal signs (Plantar response is either flexor or neutral.)</div></li><li class="half_rhythm"><div>Dystonic posture of the hands, choreic movements, head or postural tremor</div></li><li class="half_rhythm"><div>Onset between age three and 30 years</div></li><li class="half_rhythm"><div>Slow progression</div></li><li class="half_rhythm"><div>Absence of cardiac involvement, cancer predisposition, and immunodeficiency; rare or absent telangiectasia</div></li><li class="half_rhythm"><div>Absence of severe intellectual disability / cognitive regression</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div></li></ul><p><b>Laboratory features</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serum alpha-fetoprotein (AFP) concentration</b> &#x0003e;20 ng/mL (normal 0-20 ng/mL) in &#x0003e;95% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</div><div class="half_rhythm">Note: Normal serum AFP concentration is highly variable, varies over time, and in individuals with AOA2 is lower than that usually observed in individuals with <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a> [<a class="bk_pop" href="#aoa2.REF.mariani.2017.15284">Mariani et al 2017</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Increased serum total cholesterol concentration</b> &#x0003e;5.6 mmol/L (normal value: 3.5-5.8 mmol/L) in ~50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#aoa2.REF.le_ber.2004.759">Le Ber et al 2004</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Increased serum creatine kinase (CK) concentration in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Elevated immunoglobulin levels (IgG and IgA)</b> reported in several families [<a class="bk_pop" href="#aoa2.REF.gazulla.2010.118">Gazulla et al 2010</a>]</div></li></ul><p><b>Radiographic features.</b> Brain MRI examination shows marked cerebellar atrophy (including cerebellar hemispheres and vermis) with relative sparing of the brain stem.</p><p><b>Other</b></p><ul><li class="half_rhythm"><div><b>EMG</b> shows signs of axonal neuropathy in 90%-100% of individuals with AOA2 [<a class="bk_pop" href="#aoa2.REF.bohlega.2011.27">Bohlega et al 2011</a>, <a class="bk_pop" href="#aoa2.REF.hmidaben_brahim.2011.56">H'mida-Ben Brahim et al 2011</a>].</div></li><li class="half_rhythm"><div><b>Neuropathology.</b> Nerve biopsy confirms axonal neuropathy.</div></li><li class="half_rhythm"><div><b>Post-mortem brain examination</b> showed marked loss of Purkinje cells as well as mild fibrous gliosis that was more severe in the vermis than in the hemispheres [<a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al 2006</a>].</div></li></ul></div><div id="aoa2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of AOA2 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above clinical, laboratory, and radiographic features. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SETX</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1154/table/aoa2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figaoa2Tmoleculargenetictestingusedin" rid-ob="figobaoa2Tmoleculargenetictestingusedin">Table 1</a>) confirms the diagnosis.</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of AOA2 is broad, individuals with the distinctive features described in <a href="#aoa2.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#aoa2.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders with ataxia are more likely to be diagnosed using genomic testing (see <a href="#aoa2.Option_2">Option 2</a>).</p><div id="aoa2.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of AOA2 <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>SETX</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications (see <a class="figpopup" href="/books/NBK1154/table/aoa2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figaoa2Tmoleculargenetictestingusedin" rid-ob="figobaoa2Tmoleculargenetictestingusedin">Table 1</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>An ataxia <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SETX</i> and other genes of interest (see <a href="#aoa2.Differential_Diagnosis">Differential Diagnosis</a>) may be considered to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1154/table/aoa2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figaoa2Tmoleculargenetictestingusedin" rid-ob="figobaoa2Tmoleculargenetictestingusedin">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="aoa2.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by ataxia, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p><b>Exome array</b> (when clinically available) may be considered if <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="aoa2.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Ataxia with Oculomotor Apraxia Type 2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1154/table/aoa2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa2.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SETX</i></td><td headers="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~80%-92%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_aoa2.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~8%-20%&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="aoa2.TF.1.1"><p class="no_margin">See <a href="/books/n/gene.aoa2.aoa2/molgen/#TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="aoa2.TF.1.2"><p class="no_margin">See <a href="#aoa2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="aoa2.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="aoa2.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#aoa2.REF.moreira.2004.225">Moreira et al [2004]</a>, <a class="bk_pop" href="#aoa2.REF.duquette.2005.408">Duquette et al [2005]</a>, <a class="bk_pop" href="#aoa2.REF.asaka.2006.1580">Asaka et al [2006]</a>, <a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al [2006]</a>, <a class="bk_pop" href="#aoa2.REF.fogel.2006.2083">Fogel &#x00026; Perlman [2006]</a>, <a class="bk_pop" href="#aoa2.REF.lynch.2007.1775">Lynch et al [2007]</a>, <a class="bk_pop" href="#aoa2.REF.z_hlke.2007.207">Z&#x000fc;hlke et al [2007]</a>, <a class="bk_pop" href="#aoa2.REF.anheim.2008.958">Anheim et al [2008]</a>, <a class="bk_pop" href="#aoa2.REF.nicolaou.2008.28">Nicolaou et al [2008]</a>, <a class="bk_pop" href="#aoa2.REF.sch_ls.2008.495">Sch&#x000f6;ls et al [2008]</a>, <a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al [2009]</a>, <a class="bk_pop" href="#aoa2.REF.fogel.2009.448">Fogel et al [2009]</a>, <a class="bk_pop" href="#aoa2.REF.nakamura.2009.746">Nakamura et al [2009]</a>, <a class="bk_pop" href="#aoa2.REF.bohlega.2011.27">Bohlega et al [2011]</a>, <a class="bk_pop" href="#aoa2.REF.hammer.2012.241">Hammer et al [2012]</a>, <a class="bk_pop" href="#aoa2.REF.davis.2013.134">Davis et al [2013]</a>, <a class="bk_pop" href="#aoa2.REF.nanetti.2013.123">Nanetti et al [2013]</a>, <a class="bk_pop" href="#aoa2.REF.roda.2014.1627">Roda et al [2014]</a>, <a class="bk_pop" href="#aoa2.REF.newrick.2015.5">Newrick et al [2015]</a>, <a class="bk_pop" href="#aoa2.REF.pera.2015.44">Pera et al [2015]</a>, <a class="bk_pop" href="#aoa2.REF.lu.2016.179">Lu et al [2016]</a></p></div></dd><dt>5. </dt><dd><div id="aoa2.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="aoa2.TF.1.6"><p class="no_margin">Detailed in <a href="#aoa2.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b></p></div></dd></dl></div></div></div></div></div></div><div id="aoa2.Clinical_Characteristics"><h2 id="_aoa2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="aoa2.Clinical_Description"><h3>Clinical Description</h3><p>Ataxia is the first sign of ataxia with oculomotor apraxia type 2 (AOA2) and is the major cause of disability early in the disease course. Later, peripheral sensorimotor neuropathy, particularly of the lower limbs, plays a significant role in disease progression.</p><p><b>Cerebellar ataxia.</b> All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, after initial normal development, show cerebellar ataxia, with slowly progressive gait imbalance. The first symptoms are recognized between age seven and 25 years (mean 14.6 years) [<a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>, <a class="bk_pop" href="#aoa2.REF.hammer.2012.241">Hammer et al 2012</a>]. In a study of ten affected individuals from Italy, age at onset ranged between three and 30 years (mean 20.3 years) [<a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al 2006</a>].</p><p><b>Neuropathy.</b> Ninety percent to 100% of individuals with AOA2 have sensorimotor neuropathy (i.e., absent or diminished tendon reflexes and sensorimotor deficit).</p><p><b>Oculomotor apraxia.</b> Oculomotor apraxia is present in about 51% of individuals [<a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>]. It is characterized by a dissociation of eye-head movements in the "head-free" condition, in which the head reaches the lateral target before the eyes. In an Italian cohort, this feature was present in only 20% of individuals [<a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al 2006</a>], while in a study of 19 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> Algerian individuals oculomotor apraxia was present in 32% [<a class="bk_pop" href="#aoa2.REF.tazir.2009.77">Tazir et al 2009</a>]. A study of five individuals with AOA2, without head thrusts, revealed that hypometric saccades with a staircase pattern could be a more reliable sign of oculomotor apraxia than head thrust movements [<a class="bk_pop" href="#aoa2.REF.panouill_res.2013.557">Panouill&#x000e8;res et al 2013</a>].</p><p>Saccadic pursuit, gaze-evoked nystagmus, poor horizontal optokinetic nystagmus, and square-wave jerks have also been observed in several individuals [<a class="bk_pop" href="#aoa2.REF.alkaabi.2011.s2">Al-Kaabi et al 2011</a>].</p><p>In an Algerian study, 37% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals presented with convergent strabismus [<a class="bk_pop" href="#aoa2.REF.tazir.2009.77">Tazir et al 2009</a>] and in a study of 90 affected individuals worldwide, strabismus was found in 12.3% [<a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>]. Unilateral strabismus combined with nystagmus was found in an affected Algerian individual [<a class="bk_pop" href="#aoa2.REF.hmidaben_brahim.2011.56">H'mida-Ben Brahim et al 2011</a>].</p><p><b>Movement disorders.</b> Dystonic posture of the hands, choreic movements, and head or postural tremor are observed in about 14% of individuals [<a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>, <a class="bk_pop" href="#aoa2.REF.tazir.2009.77">Tazir et al 2009</a>]. The severity of the movement disorders persists in individuals with AOA2 in contrast to the movement disorder in individuals with <a href="/books/n/gene/aoa/">ataxia with oculomotor apraxia type 1</a> (AOA1), in which chorea tends to disappear with time [<a class="bk_pop" href="#aoa2.REF.le_ber.2004.759">Le Ber et al 2004</a>]. In the Italian study, extrapyramidal symptoms (including choreiform head movements, truncal dystonia, and head tremor) were reported in 20% of individuals; however, they rapidly disappeared as the disease progressed [<a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al 2006</a>]. In the French-Canadian group of individuals tremor was an inconsistent feature present in 57% [<a class="bk_pop" href="#aoa2.REF.duquette.2005.408">Duquette et al 2005</a>].</p><p>Rarely, involuntary movements have been reported as a prominent presenting sign of AOA2, although they are accompanied by ataxia in almost all individuals. Two individuals had upper limb dystonia as an initial sign. Two sibs presented with prominent chorea of the trunk and face. One individual had <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> head tremor as the initial sign at age nine years [<a class="bk_pop" href="#aoa2.REF.pearson.2016.368">Pearson 2016</a>].</p><p>Pyramidal signs were found in 20.5% of individuals with AOA2 [<a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>]. Plantar response was either flexor or neutral [<a class="bk_pop" href="#aoa2.REF.koenig.2007">Koenig &#x00026; Moreira 2007</a>]</p><p><b>Intellect.</b> Mild cognitive impairment is present in some individuals [<a class="bk_pop" href="#aoa2.REF.le_ber.2004.759">Le Ber et al 2004</a>]; none have had severe intellectual disability or dementia, even after long disease duration [<a class="bk_pop" href="#aoa2.REF.le_ber.2004.759">Le Ber et al 2004</a>]. In the <a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al [2006]</a> study, three of ten persons presented with mild intellectual impairment with onset around age 50 years. A study of the neuropsychological pro&#x0fb01;le of an individual age 45 years with AOA2 indicated that the pathogenesis of the cerebrocerebellar circuit in AOA2 was responsible for the weaker coordination of complex cognitive functions such as working memory, executive functions, speech, and sequence learning [<a class="bk_pop" href="#aoa2.REF.kliv_nyi.2012.125">Kliv&#x000e9;nyi et al 2012</a>].</p><p><b>Other.</b> Deep sensory loss [<a class="bk_pop" href="#aoa2.REF.le_ber.2004.759">Le Ber et al 2004</a>, <a class="bk_pop" href="#aoa2.REF.fogel.2009.448">Fogel et al 2009</a>, <a class="bk_pop" href="#aoa2.REF.hmidaben_brahim.2011.56">H'mida-Ben Brahim et al 2011</a>], extensor plantar reflexes, swallowing difficulties, and sphincter disturbances are observed in some individuals [<a class="bk_pop" href="#aoa2.REF.le_ber.2004.759">Le Ber et al 2004</a>]. Various signs of extraneurologic involvement including early-onset menopause [<a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al 2006</a>], ovarian failure [<a class="bk_pop" href="#aoa2.REF.gazulla.2009.481">Gazulla et al 2009</a>], dermatofibrosarcoma protuberans [<a class="bk_pop" href="#aoa2.REF.sch_ls.2008.495">Sch&#x000f6;ls et al 2008</a>], polycystic ovarian syndrome [<a class="bk_pop" href="#aoa2.REF.fogel.2009.448">Fogel et al 2009</a>], and amenorrhea secondary to hypogonadotropic hypogonadism [<a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>] have been reported.</p><p><b>Life span.</b> In individuals studied to date, disease duration ranged between two and 53 years, corresponding to the maximum age of last examination, which was at 79 years.</p><p><b>Neuropathology.</b> Chronic axonal neuropathy with preferential loss of large (and to a lesser degree small) myelinated fibers is detected in sural nerve biopsies [<a class="bk_pop" href="#aoa2.REF.alkaabi.2011.s2">Al-Kaabi et al 2011</a>].</p><p>Postmortem brain examination in an Italian patient age 79 years who died of heart failure revealed reduction in the overall size of the brain, including atrophy of the cerebellar folia and marked widening of the sulci [<a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al 2006</a>]. Cerebellar atrophy was most evident at the level of the vermis and the anterior lobe. The brain stem and spinal cord were slightly reduced in size without other anomalies. The substantia nigra appeared normally pigmented. Atheromatous plaques were present in all the arteries of the circle of Willis. Histologic examination showed normal cortical neurons (both in number and shape), marked loss of Purkinje cells in the cerebellar cortex, and mild fibrous gliosis that was more severe in the vermis than in the hemispheres. No inclusions or torpedos were found. The neurons of the dentate nuclei were slightly reduced in number. Chromatolysis of the oculomotor and raphe nuclei was observed in the brain stem. The inferior and accessory olives appeared relatively spared. In the spinal cord severe demyelination of the gracilis and cuneatus funiculi and degeneration of Clarke's columns with gliosis were observed. A study of 3 Tesla (3T) brain MRI examinations of five individuals with AOA2 revealed significant atrophy of all cerebellar lobules. The degree of atrophy was highest in the vermis, consistent with the oculomotor presentation, and the anterior lobe, consistent with kinetic limb ataxia. An absence of hypointensity of the iron signal on susceptibility-weighted imaging (SWI) was seen in the dentate nucleus of all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#aoa2.REF.frismand.2013.542">Frismand et al 2013</a>].</p><p><b>Neurochemical patterns.</b> Short-echo, single-voxel proton ((1)H) magnetic resonance spectroscopy performed in nine individuals with AOA2 showed total N-acetylaspartate levels in the cerebellum strongly correlated with the Friedreich Ataxia Rating Scale (FARS), which may be used as a measure of impairment in those with ataxia [<a class="bk_pop" href="#aoa2.REF.iltis.2010.200">Iltis et al 2010</a>].</p></div><div id="aoa2.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>A study of 90 individuals with AOA2 found that pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in the helicase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> caused less severe AOA2 phenotypes than missense variants outside of this domain, or deletions, or truncating variants of <i>SETX</i>. However, individuals with pathogenic truncating or missense variants outside of the helicase domain had a lower frequency of pyramidal signs &#x02013; a finding that may reflect masking of the pyramidal signs by severe motor neuropathy [<a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>].</p></div><div id="aoa2.Nomenclature"><h3>Nomenclature</h3><p>AOA2 was first known as "ataxia with later onset and high level of alpha-fetoprotein."</p></div><div id="aoa2.Prevalence"><h3>Prevalence</h3><p>The prevalence of <a class="figpopup" href="/books/NBK1154/table/aoa2.T.setx_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figaoa2Tsetxpathogenicvariantsdiscusse" rid-ob="figobaoa2Tsetxpathogenicvariantsdiscusse">p.Leu1976Arg</a> and <a class="figpopup" href="/books/NBK1154/table/aoa2.T.setx_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figaoa2Tsetxpathogenicvariantsdiscusse" rid-ob="figobaoa2Tsetxpathogenicvariantsdiscusse">p.Glu65Lys</a> pathogenic variants was studied by <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a> 154 samples from the Gasp&#x000e9;sie region, including 82 French-Canadian and 72 Anglo-Norman control samples [<a class="bk_pop" href="#aoa2.REF.duquette.2005.408">Duquette et al 2005</a>]. In this study, five individuals (3 of Anglo-Norman and 2 of French-Canadian backgrounds) were carriers of the p.Leu1976Arg common French-Canadian variant and none was a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of the rarer p.Glu65Lys variant. According to these results, the <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for the p.Leu1976Arg variant is estimated to be 3.5% (1:28) for Qu&#x000e9;b&#x000e9;cois of Anglo-Norman origin and 2.1% (1:47) for the French-Canadian population of Gasp&#x000e9;sie. No individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the pathogenic variants p.Leu1976Arg or p.Glu65Lys were identified.</p><p>A study of 102 individuals with suspected <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> cerebellar ataxia from Eastern Europe (95 from Alsace, in eastern France) reported seven individuals with AOA2 (6.9%). AOA2 prevalence in Alsace was inferred to be slightly less than 1:400,000 [<a class="bk_pop" href="#aoa2.REF.anheim.2010.1">Anheim et al 2010</a>].</p></div></div><div id="aoa2.Genetically_Related_Allelic_Disorde"><h2 id="_aoa2_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><b>Juvenile amyotrophic lateral sclerosis (ALS4)</b> (also known as distal hereditary motor neuronopathy with pyramidal features, or dHMN) is associated with three different <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants (p.Thr3Ile, p.Leu389Ser, and p.Arg2136His) in <i>SETX</i> [<a class="bk_pop" href="#aoa2.REF.chen.2004.1128">Chen et al 2004</a>]. ALS4 is a rare <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of <a href="/books/n/gene/als-overview/">amyotrophic lateral sclerosis</a> (ALS) characterized by severe distal muscle weakness and atrophy, normal sensation, and pyramidal signs associated with degeneration of motor neurons in the brain and spinal cord. Individuals with ALS4 usually have onset before age 25 years, a slow rate of progression, sparing of bulbar and respiratory muscles, and a normal life span.</p><p><b>An <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of ataxia</b> appears to be associated with two <i>SETX</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration p.[Asn603Asp;Gln653Lys] by a mother and daughter [<a class="bk_pop" href="#aoa2.REF.bassuk.2007.45">Bassuk et al 2007</a>]. Both had cerebellar ataxia with atrophy of the cerebellum, dysarthria, oculomotor defects (saccadic pursuits and gaze-evoked nystagmus), and tremor. The mother had onset of cerebellar ataxia at age 13 years, the daughter at age three years. Mental status, reflexes, sensation, muscle tone, and serum concentration of alpha-fetoprotein and creatine kinase were within normal range.</p></div><div id="aoa2.Differential_Diagnosis"><h2 id="_aoa2_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Childhood.</b> The diagnosis of ataxia with oculomotor apraxia type 2 (AOA2) can be difficult to establish in young children because not all features of the disease are present or apparent. AOA2 in childhood needs to be distinguished from the following disorders:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/aoa/">Ataxia with oculomotor apraxia type 1</a> (AOA1) is a progressive cerebellar ataxia characterized by childhood onset followed by oculomotor apraxia and a severe primary motor peripheral axonal motor neuropathy. The first manifestation is progressive gait imbalance (mean age of onset: 4.3 years; range: 2-10 years), followed by dysarthria, then upper-limb dysmetria with mild intention tremor. Oculomotor apraxia, usually noticed a few years after the onset of ataxia, progresses to external ophthalmoplegia. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have generalized areflexia followed by a peripheral neuropathy and quadriplegia with loss of ambulation about seven to ten years after onset. Hands and feet are short and atrophic. Chorea and upper-limb dystonia are common. Intellect remains normal in some individuals; in others, different degrees of cognitive impairment have been observed. After a long disease duration (&#x0003e;10-15 years), low serum concentration of albumin and high serum concentration of total cholesterol are observed. AOA1 is caused by pathogenic variants in <i>APTX</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding aprataxin.</div></li><li class="half_rhythm"><div>Ataxia with oculomotor apraxia type 4 (AOA4) (OMIM <a href="https://omim.org/entry/616267" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616267</a>) a form of recessive ataxia characterized by mean age at onset of 4.3 years, marked extrapyramidal manifestations, rapid progression, low or normal albumin levels, normal or high cholesterol levels, and elevated alpha-fetoprotein in some individuals. AOA4 is caused by pathogenic variants in <i>PNKP</i>.</div></li><li class="half_rhythm"><div>When oculomotor apraxia and/or high serum concentrations of alpha-fetoprotein are present, <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a> (caused by pathogenic variants in <i>ATM</i>) and ataxia-telangiectasia-like disorder (caused by pathogenic variants in <i>MRE11</i>; OMIM <a href="https://www.omim.org/entry/604391" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604391</a>) should also be considered.</div></li></ul><p><b>Adolescence</b></p><ul><li class="half_rhythm"><div><a href="/books/n/gene/friedreich/">Friedreich ataxia</a> (FRDA) can be excluded on clinical grounds, as oculomotor apraxia is not observed in FRDA and cerebellar atrophy is not observed on MRI in FRDA early in the disease course. Molecular genetic testing of <i>FRDA</i> can detect pathogenic variants in virtually 100% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/aved/">Ataxia with vitamin E deficiency</a> (AVED) and primary <a href="/books/n/gene/coq10-def/">coenzyme Q<sub>10</sub> deficiency</a> should be considered because they are treatable disorders.</div></li></ul><p><b>Adulthood.</b> In <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family), the possibility of <a href="/books/n/gene/sca2/">spinocerebellar ataxia type 2</a> (SCA2) (a dominant form of ataxia which also associates cerebellar ataxia with slow eye movements) can be excluded by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>SCA2</i>.</p></div><div id="aoa2.Management"><h2 id="_aoa2_Management_">Management</h2><div id="aoa2.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with oculomotor apraxia type 2 (AOA2), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Neurologic examination including assessment of cranial nerve function, gait and limb ataxia, coordination, tone, strength, reflexes, and sensory perception</div></li><li class="half_rhythm"><div>Ophthalmologic examination</div></li><li class="half_rhythm"><div>Physical therapy and occupational therapy assessment of strength and balance</div></li><li class="half_rhythm"><div>Assessment of cognitive function</div></li><li class="half_rhythm"><div>Serum cholesterol</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li><li class="half_rhythm"><div>Serum alpha-fetoprotein (AFP) concentration, if not evaluated previously</div></li></ul></div><div id="aoa2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Physical therapy may be helpful, particularly for disabilities resulting from peripheral neuropathy.</p><p>A wheelchair is usually necessary for mobility by age 30 years.</p><p>Educational support (e.g., use of a computer with speech recognition and special keyboard for typing) should be provided to compensate for difficulties in reading (caused by oculomotor apraxia) and in writing (caused by upper-limb ataxia).</p></div><div id="aoa2.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>A low-cholesterol diet is advised to reduce the risk of adverse health effects of hypercholesterolemia</p></div><div id="aoa2.Surveillance"><h3>Surveillance</h3><p>Routine visits to the attending neurologist are indicated.</p><p>Ophthalmologic surveillance is recommended.</p><p>Cholesterol level should be monitored regularly.</p></div><div id="aoa2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#aoa2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="aoa2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="aoa2.Genetic_Counseling"><h2 id="_aoa2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="aoa2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Ataxia with oculomotor apraxia type 2 (AOA2) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="aoa2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>SETX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with AOA2 are not known to reproduce.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>SETX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="aoa2.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SETX</i> pathogenic variants in the family.</p></div><div id="aoa2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="aoa2.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SETX</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="aoa2.Resources"><h2 id="_aoa2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>euro-ATAXIA (European Federation of Hereditary Ataxias)</b></div><div>Ataxia UK</div><div>Lincoln House, Kennington Park, 1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 207 582 1444</div><div><b>Email:</b> smillman@ataxia.org.uk</div><div><a href="https://www.euroataxia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.euroataxia.org</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>CoRDS Registry</b></div><div>Sanford Research</div><div>2301 East 60th Street North</div><div>Sioux Falls SD 57104</div><div><b>Phone:</b> 605-312-6423</div><div><b>Email:</b> sanfordresearch@sanfordhealth.org</div><div><a href="http://www.sanfordresearch.org/SpecialPrograms/cords/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CoRDS Registry</a></div></li></ul></div><div id="aoa2.Molecular_Genetics"><h2 id="_aoa2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="aoa2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Ataxia with Oculomotor Apraxia Type 2: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1154/table/aoa2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_aoa2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_aoa2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_aoa2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_aoa2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_aoa2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_aoa2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_aoa2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/23064" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SETX</i></a></td><td headers="hd_b_aoa2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=23064" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9q34<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_aoa2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q7Z333" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Probable helicase senataxin</a></td><td headers="hd_b_aoa2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=1&#x00026;geneId=EG23064" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALS mutation database (SETX)</a><br /><a href="http://www.molgen.ua.ac.be/CMTMutations/Mutations/Contexts.cfm?ID=35" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IPN Mutations, ALS4 (SETX)</a><br /><a href="http://databases.lovd.nl/shared/genes/SETX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SETX database</a><br /><a href="https://databases.lovd.nl/shared/genes/SETX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SETX homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_aoa2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SETX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SETX</a></td><td headers="hd_b_aoa2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SETX[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SETX</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="aoa2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="aoa2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Ataxia with Oculomotor Apraxia Type 2 (<a href="/omim/606002,608465" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1154/table/aoa2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606002" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606002</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY 2; SCAN2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608465" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608465</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SENATAXIN; SETX</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>SETX</i> is composed of 24 coding and two noncoding exons (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_015046.6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015046.6</a>). Multiple transcript variants and <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> are described; for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1154/#aoa2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 100 pathogenic variants have been found in families worldwide. The majority are <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants and small deletions and insertions. There have also been multiple reports of gross deletions, insertions, duplications, and even a complex <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#aoa2.REF.criscuolo.2006.1207">Criscuolo et al 2006</a>, <a class="bk_pop" href="#aoa2.REF.arning.2008.295">Arning et al 2008</a>, <a class="bk_pop" href="#aoa2.REF.anheim.2009.2688">Anheim et al 2009</a>, <a class="bk_pop" href="#aoa2.REF.bernard.2009.87">Bernard et al 2009</a>, <a class="bk_pop" href="#aoa2.REF.nanetti.2013.123">Nanetti et al 2013</a>] (see also <a href="/books/n/gene.aoa2.aoa2/molgen/#TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>HGMD</b>]. Such rearrangements accounted for 8%-20% of variants in different studies, with the largest study having 8% (4/51) [<a class="bk_pop" href="#aoa2.REF.bernard.2009.87">Bernard et al 2009</a>].</p><div id="aoa2.T.setx_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>SETX</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1154/table/aoa2.T.setx_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa2.T.setx_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.193G&#x0003e;A</td><td headers="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu65Lys</td><td headers="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_015046.6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015046<wbr style="display:inline-block"></wbr>​.6</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_055861.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_055861<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5927T&#x0003e;G</td><td headers="hd_h_aoa2.T.setx_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu1976Arg</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Probable helicase senataxin is a ubiquitously expressed 2,677 amino-acid enzyme encoded by <i>SETX</i>. Senataxin is strongly conserved throughout evolution and has been implicated in a large variety of biologic processes, including transcription, meiosis completion, neurogenesis, antiviral response, and maintenance of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> integrity. In general, senataxin, likely complexed with other proteins, has a critical role in RNA metabolism to maintain genome stability in both proliferating cells and post-mitotic cells.</p><p>Because investigating the roles of senataxin in human and model organisms is an active area of research, the authors direct the reader to both recent reviews [<a class="bk_pop" href="#aoa2.REF.lavin.2013.e25230">Lavin et al 2013</a>, <a class="bk_pop" href="#aoa2.REF.bennett.2015.127">Bennett &#x00026; La Spada 2015</a>, <a class="bk_pop" href="#aoa2.REF.groh.2017.3181">Groh et al 2017</a>] and a limited selection of publications of primary data [<a class="bk_pop" href="#aoa2.REF.miller.2015.485">Miller et al 2015</a>, <a class="bk_pop" href="#aoa2.REF.sariki.2016.4056">Sariki et al 2016</a>, <a class="bk_pop" href="#aoa2.REF.bennett.2018.425">Bennett et al 2018</a>, <a class="bk_pop" href="#aoa2.REF.cohen.2018.533">Cohen et al 2018</a>, <a class="bk_pop" href="#aoa2.REF.grunseich.2018.426">Grunseich et al 2018</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Importantly, the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants to date cluster within the N-terminus and helicase domains marking these regions as being functionally important. The <i>SETX</i> deletions, insertions, and duplications in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals indicate that loss of senataxin function is the cause of AOA2.</p></div><div id="aoa2.References"><h2 id="_aoa2_References_">References</h2><div id="aoa2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.alkaabi.2011.s2">Al-Kaabi AM, Bolton CF, Fogel BL, Wahnich A, Nicolle DA, Nicolle MW, Gatti RA, Hahn AF. Longitudinal clinical and electrophysiological evaluation of a patient with ataxia with oculomotor apraxia type 2 and a novel splice site mutation in the senataxin gene. <span><span class="ref-journal">J Periph Nerv Sys. </span>2011;<span class="ref-vol">16</span>:S2–S3.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.anheim.2010.1">Anheim M, Fleury M, Monga B, Laugel V, Chaigne D, Rodier G, Ginglinger E, Boulay C, Courtois S, Drouot N, Fritsch M, Delaunoy JP, Stoppa-Lyonnet D, Tranchant C, Koenig M. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. <span><span class="ref-journal">Neurogenetics. </span>2010;<span class="ref-vol">11</span>:1–12.</span> [<a href="/pubmed/19440741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19440741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.anheim.2008.958">Anheim M, Fleury MC, Franques J, Moreira MC, Delaunoy JP, Stoppa-Lyonnet D, Koenig M, Tranchant C. Clinical and molecular findings of ataxia with oculomotor apraxia type 2 in 4 families. <span><span class="ref-journal">Arch Neurol. </span>2008;<span class="ref-vol">65</span>:958–62.</span> [<a href="/pubmed/18625865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18625865</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.anheim.2009.2688">Anheim M, Monga B, Fleury M, Charles P, Barbot C, Salih M, Delaunoy JP, Fritsch M, Arning L, Synofzik M, Sch&#x000f6;ls L, Sequeiros J, Goizet C, Marelli C, Le Ber I, Koht J, Gazulla J, De Bleecker J, Mukhtar M, Drouot N, Ali-Pacha L, Benhassine T, Chbicheb M, M'Zahem A, Hamri A, Chabrol B, Pouget J, Murphy R, Watanabe M, Coutinho P, Tazir M, Durr A, Brice A, Tranchant C, Koenig M. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>:2688–98.</span> [<a href="/pubmed/19696032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19696032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.arning.2008.295">Arning L, Sch&#x000f6;ls L, Cin H, Souquet M, Epplen JT, Timmann D. Identification and characterisation of a large Senataxin (SETX) gene duplication in ataxia with ocular apraxia type 2 (AOA2). <span><span class="ref-journal">Neurogenetics. </span>2008;<span class="ref-vol">9</span>:295–9.</span> [<a href="/pubmed/18663494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18663494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.asaka.2006.1580">Asaka T, Yokoji H, Ito J, Yamaguchi K, Matsushima A. Autosomal recessive ataxia with peripheral neuropathy and elevated AFP: novel mutations in SETX. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">66</span>:1580–1.</span> [<a href="/pubmed/16717225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16717225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.bassuk.2007.45">Bassuk AG, Chen YZ, Batish SD, Nagan N, Opal P, Chance PF, Bennett CL. In cis autosomal dominant mutation of Senataxin associated with tremor/ataxia syndrome. <span><span class="ref-journal">Neurogenetics. </span>2007;<span class="ref-vol">8</span>:45–49.</span> [<a href="/pubmed/17096168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17096168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.bennett.2018.425">Bennett CL, Dastidar SG, Ling SC, Malik B, Ashe T, Wadhwa M, Miller DB, Lee C, Mitchell MB, van Es MA, Grunseich C, Chen Y, Sopher BL, Greensmith L, Cleveland DW, La Spada AR. Senataxin mutations elicit motor neuron degeneration phenotypes and yield TDP-43 mislocalization in ALS4 mice and human patients. <span><span class="ref-journal">Acta Neuropathol. </span>2018;<span class="ref-vol">136</span>:425–43.</span> [<a href="/pmc/articles/PMC6098723/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6098723</span></a>] [<a href="/pubmed/29725819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29725819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.bennett.2015.127">Bennett CL, La Spada AR. Unwinding the role of senataxin in neurodegeneration. <span><span class="ref-journal">Discov Med. </span>2015;<span class="ref-vol">19</span>:127–36.</span> [<a href="/pubmed/25725227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25725227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.bernard.2009.87">Bernard V, Minnerop M, B&#x000fc;rk K, Kreuz F, Gillessen-Kaesbach G, Z&#x000fc;hlke C. Exon deletions and intragenic insertions are not rare in ataxia with oculomotor apraxia 2. <span><span class="ref-journal">BMC Med Genet. </span>2009;<span class="ref-vol">10</span>:87.</span> [<a href="/pmc/articles/PMC2749023/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2749023</span></a>] [<a href="/pubmed/19744353" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19744353</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.bohlega.2011.27">Bohlega SA, Shinwari JM, Al Sharif LJ, Khalil DS, Alkhairallah TS, Al Tassan NA. Clinical and molecular characterization of ataxia with oculomotor apraxia patients in Saudi Arabia. <span><span class="ref-journal">BMC Med Genet. </span>2011;<span class="ref-vol">12</span>:27.</span> [<a href="/pmc/articles/PMC3048493/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3048493</span></a>] [<a href="/pubmed/21324166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21324166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.chen.2004.1128">Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, Dierick I, Abel A, Kennerson ML, Rabin BA, Nicholson GA, Auer-Grumbach M, Wagner K, De Jonghe P, Griffin JW, Fischbeck KH, Timmerman V, Cornblath DR, Chance PF. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:1128–35.</span> [<a href="/pmc/articles/PMC1182077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1182077</span></a>] [<a href="/pubmed/15106121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15106121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.cohen.2018.533">Cohen S, Puget N, Lin YL, Clouaire T, Aguirrebengoa M, Rocher V, Pasero P, Canitrot Y, Legube G. Senataxin resolves RNA:DNA hybrids forming at DNA double-strand breaks to prevent translocations. <span><span class="ref-journal">Nat Commun. </span>2018;<span class="ref-vol">9</span>:533.</span> [<a href="/pmc/articles/PMC5803260/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5803260</span></a>] [<a href="/pubmed/29416069" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29416069</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.criscuolo.2006.1207">Criscuolo C, Chessa L, Di Giandomenico S, Mancini P, Sacca F, Grieco GS, Piane M, Barbieri F, De Michele G, Banfi S, Pierelli F, Rizzuto N, Santorelli FM, Gallosti L, Filla A, Casali C. Ataxia with oculomotor apraxia type 2: a clinical, pathologic, and genetic study. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">66</span>:1207–10.</span> [<a href="/pubmed/16636238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16636238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.davis.2013.134">Davis MY, Keene CD, Swanson PD, Sheehy C, Bird TD. Novel mutations in ataxia telangiectasia and AOA2 associated with prolonged survival. <span><span class="ref-journal">J Neurol Sci. </span>2013;<span class="ref-vol">335</span>:134–8.</span> [<a href="/pmc/articles/PMC4017341/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4017341</span></a>] [<a href="/pubmed/24090759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24090759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.duquette.2005.408">Duquette A, Roddier K, McNabb-Baltar J, Gosselin I, St-Denis A, Dicaire MJ, Loisel L, Labuda D, Marchand L, Mathieu J, Bouchard JP, Brais B. Mutations in senataxin responsible for Quebec cluster of ataxia with neuropathy. <span><span class="ref-journal">Ann Neurol. </span>2005;<span class="ref-vol">57</span>:408–14.</span> [<a href="/pubmed/15732101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15732101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.fogel.2009.448">Fogel BL, Lee JY, Perlman S. Aberrant splicing of the senataxin gene in a patient with ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">Cerebellum. </span>2009;<span class="ref-vol">8</span>:448–53.</span> [<a href="/pmc/articles/PMC2788137/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2788137</span></a>] [<a href="/pubmed/19727998" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19727998</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.fogel.2006.2083">Fogel BL, Perlman S. Novel mutations in the senataxin DNA/RNA helicase domain in ataxia with oculomotor apraxia 2. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:2083–4.</span> [<a href="/pubmed/17159128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17159128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.frismand.2013.542">Frismand S, Salem H, Panouilleres M, P&#x000e9;lisson D, Jacobs S, Vighetto A, Cotton F, Tilikete C. MRI findings in AOA2: Cerebellar atrophy and abnormal iron detection in dentate nucleus. <span><span class="ref-journal">Neuroimage Clin. </span>2013;<span class="ref-vol">2</span>:542–8.</span> [<a href="/pmc/articles/PMC3777765/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3777765</span></a>] [<a href="/pubmed/24179805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24179805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.gazulla.2009.481">Gazulla J, Benavente I, L&#x000f3;pez-Fraile IP, Modrego P, Koenig M. Sensorimotor neuronopathy in ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">Muscle Nerve. </span>2009;<span class="ref-vol">40</span>:481–5.</span> [<a href="/pubmed/19618424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19618424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.gazulla.2010.118">Gazulla J, Benavente I, L&#x000f3;pez-Fraile IP, Tordesillas C, Modrego P, Alonso I, Pinto-Basto J. Sensory neuronopathy in ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">J Neurol Sci. </span>2010;<span class="ref-vol">298</span>:118–20.</span> [<a href="/pubmed/20869730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20869730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.groh.2017.3181">Groh M, Albulescu LO, Cristini A, Gromak N. Senataxin: Genome guardian at the interface of transcription and neurodegeneration. <span><span class="ref-journal">J Mol Biol. </span>2017;<span class="ref-vol">429</span>:3181–95.</span> [<a href="/pubmed/27771483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27771483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.grunseich.2018.426">Grunseich C, Wang IX, Watts JA, Burdick JT, Guber RD, Zhu Z, Bruzel A, Lanman T, Chen K, Schindler AB, Edwards N, Ray-Chaudhury A, Yao J, Lehky T, Piszczek G, Crain B, Fischbeck KH, Cheung VG. Senataxin mutation reveals how R-loops promote transcription by blocking DNA methylation at gene promoters. <span><span class="ref-journal">Mol Cell. </span>2018;<span class="ref-vol">69</span>:426–37.e7.</span> [<a href="/pmc/articles/PMC5815878/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5815878</span></a>] [<a href="/pubmed/29395064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29395064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.hammer.2012.241">Hammer MB, Eleuch-Fayache G, Gibbs JR, Arepalli SK, Chong SB, Sassi C, Bouhlal Y, Hentati F, Amouri R, Singleton AB. Clinical and molecular findings of ataxia with oculomotor apraxia type 2 (AOA2) in 5 Tunisian families. <span><span class="ref-journal">Diagn Mol Pathol. </span>2012;<span class="ref-vol">21</span>:241–5.</span> [<a href="/pubmed/23111195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23111195</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.hmidaben_brahim.2011.56">H'mida-Ben Brahim D, M'zahem A, Assoum M, Bouhlal Y, Fattori F, Anheim M, Ali-Pacha L, Ferrat F, Chaouch M, Lagier-Tourenne C, Drouot N, Thibaut C, Benhassine T, Sifi Y, Stoppa-Lyonnet D, N'Guyen K, Poujet J, Hamri A, Hentati F, Amouri R, Santorelli FM, Tazir M, Koenig M. Molecular diagnosis of known recessive ataxias by homozygosity mapping with SNP arrays. <span><span class="ref-journal">J Neurol. </span>2011;<span class="ref-vol">258</span>:56–67.</span> [<a href="/pubmed/20798953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20798953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.iltis.2010.200">Iltis I, Hutter D, Bushara KO, Clark HB, Gross M, Eberly LE, Gomez CM, Oz G. H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">Brain Res. </span>2010;<span class="ref-vol">1358</span>:200–10.</span> [<a href="/pmc/articles/PMC2949538/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2949538</span></a>] [<a href="/pubmed/20713024" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20713024</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.kliv_nyi.2012.125">Kliv&#x000e9;nyi P, Nemeth D, Sefcsik T, Janacsek K, Hoffmann I, Peter Haden G, Londe Z, Vecsei L. Cognitive functions in ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">Front Neurol. </span>2012;<span class="ref-vol">3</span>:125.</span> [<a href="/pmc/articles/PMC3449493/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3449493</span></a>] [<a href="/pubmed/23015802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23015802</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.koenig.2007">Koenig M, Moreira MC. Recessive ataxia plus oculomotor apraxia syndromes. In: Brice A, Pulst S, Schapira AHV, Samuels MA (eds) <em>Spinocerebellar Degenerations: The Ataxias and Spastic Paraplegias</em>. 1 ed. Philadelphia, PA: Butterworth Heinemann Elsevier 2007;31:244-54.</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.lavin.2013.e25230">Lavin MF, Yeo AJ, Becherel J. Senataxin protects the genome Implications for neurodegeneration and other abnormalities. <span><span class="ref-journal">Rare Dis. </span>2013;<span class="ref-vol">1</span>:e25230.</span> [<a href="/pmc/articles/PMC3927485/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3927485</span></a>] [<a href="/pubmed/25003001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25003001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.le_ber.2004.759">Le Ber I, Bouslam N, Rivaud-Pechoux S, Guimaraes J, Benomar A, Chamayou C, Goizet C, Moreira MC, Klur S, Yahyaoui M, Agid Y, Koenig M, Stevanin G, Brice A, Durr A. Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. <span><span class="ref-journal">Brain. </span>2004;<span class="ref-vol">127</span>:759–67.</span> [<a href="/pubmed/14736755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14736755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.lu.2016.179">Lu C, Zheng YC, Dong Y, Li HF. Identification of novel senataxin mutations in Chinese patients with autosomal recessive cerebellar ataxias by targeted next-generation sequencing. <span><span class="ref-journal">BMC Neurol. </span>2016;<span class="ref-vol">16</span>:179.</span> [<a href="/pmc/articles/PMC5029030/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5029030</span></a>] [<a href="/pubmed/27644330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27644330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.lynch.2007.1775">Lynch DR, Braastad CD, Nagan N. Ovarian failure in ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">Am J Med Genet A. </span>2007;<span class="ref-vol">143A</span>:1775–7.</span> [<a href="/pubmed/17593543" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17593543</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.mariani.2017.15284">Mariani LL, Rivaud-P&#x000e9;choux S, Charles P, Ewenczyk C, Meneret A, Monga BB, Fleury MC, Hainque E, Maisonobe T, Degos B, Echaniz-Laguna AO, Renaud M, Wirth T, Grabli D, Brice A, Vidailhet M, Stoppa-Lyonnet D, Dubois-d&#x02019;Enghien C, Le Ber I, Koenig M, Roze E, Tranchant C, Durr A, Gaymard B, Anheim M. Comparing ataxias with oculomotor apraxia: a multimodal study of AOA1, AOA2 and AT focusing on video-oculography and alpha-fetoprotein. <span><span class="ref-journal">Sci Rep. </span>2017;<span class="ref-vol">7</span>:15284.</span> [<a href="/pmc/articles/PMC5681651/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5681651</span></a>] [<a href="/pubmed/29127364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29127364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.miller.2015.485">Miller MS, Rialdi A, Ho JS, Tilove M, Martinez-Gil L, Moshkina NP, Peralta Z, Noel J, Melegari C, Maestre A, Mitsopoulos P, Madrenas J, Heinz S, Benner C, Young JA, Feagins AR, Basler CF, Fernandez-Sesma A, Becherel OJ, Lavin MF, van Bakel H, Marazzi I. The helicase senataxin suppresses the antiviral transcriptional response and controls viral biogenesis. <span><span class="ref-journal">Nat Immunol. </span>2015;<span class="ref-vol">16</span>:485–94.</span> [<a href="/pmc/articles/PMC4406851/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4406851</span></a>] [<a href="/pubmed/25822250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25822250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.moreira.2004.225">Moreira MC, Klur S, Watanabe M, N&#x000e9;meth AH, Le Ber I, Moniz JC, Tranchant C, Aubourg P, Tazir M, Schols L, Pandolfo M, Schulz JB, Pouget J, Calvas P, Shizuka-Ikeda M, Shoji M, Tanaka M, Izatt L, Shaw CE, M'Zahem A, Dunne E, Bomont P, Benhassine T, Bouslam N, Stevanin G, Brice A, Guimaraes J, Mendonca P, Barbot C, Coutinho P, Sequeiros J, Durr A, Warter JM, Koenig M. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. <span><span class="ref-journal">Nat Genet. </span>2004;<span class="ref-vol">36</span>:225–7.</span> [<a href="/pubmed/14770181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14770181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.nakamura.2009.746">Nakamura K, Yoshida K, Makishita H, Kitamura E, Hashimoto S, Ikeda S. A novel nonsense mutation in a Japanese family with ataxia with oculomotor apraxia type 2 (AOA2). <span><span class="ref-journal">J Hum Genet. </span>2009;<span class="ref-vol">54</span>:746–8.</span> [<a href="/pubmed/19893583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19893583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.nanetti.2013.123">Nanetti L, Cavalieri S, Pensato V, Erbetta A, Pareyson D, Panzeri M, Zorzi G, Antozzi C, Moroni I, Gellera C, Brusco A, Mariotti C. SETX mutations are a frequent genetic cause of juvenile and adult onset cerebellar ataxia with neuropathy and elevated serum alpha-fetoprotein. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013;<span class="ref-vol">8</span>:123.</span> [<a href="/pmc/articles/PMC3751478/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3751478</span></a>] [<a href="/pubmed/23941260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23941260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.newrick.2015.5">Newrick L, Taylor M, Hadjivassiliou M. Pseudodominant AOA2. <span><span class="ref-journal">Cerebellum Ataxias. </span>2015;<span class="ref-vol">2</span>:5.</span> [<a href="/pmc/articles/PMC4552145/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4552145</span></a>] [<a href="/pubmed/26331048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26331048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.nicolaou.2008.28">Nicolaou P, Georghiou A, Votsi C, Middleton LT, Zamba-Papanicolaou E, Christodoulou K. A novel c.5308_5311delGAGA mutation in senataxin in a Cypriot family with an autosomal recessive cerebellar ataxia. <span><span class="ref-journal">BMC Med Genet. </span>2008;<span class="ref-vol">9</span>:28.</span> [<a href="/pmc/articles/PMC2330029/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2330029</span></a>] [<a href="/pubmed/18405395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18405395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.panouill_res.2013.557">Panouill&#x000e8;res M, Frismand S, Sillan O, Urquizar C, Vighetto A, P&#x000e9;lisson D, Tilikete C. Saccades and eye-head coordination in ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">Cerebellum. </span>2013;<span class="ref-vol">12</span>:557–67.</span> [<a href="/pubmed/23475383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23475383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.pearson.2016.368">Pearson TS. More than ataxia: hyperkinetic movement disorders in childhood autosomal recessive ataxia syndromes. <span><span class="ref-journal">Tremor Other Hyperkinet Mov (N Y). </span>2016;<span class="ref-vol">6</span>:368.</span> [<a href="/pmc/articles/PMC4950223/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4950223</span></a>] [<a href="/pubmed/27536460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27536460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.pera.2015.44">Pera J, Lechner S, Biskup S, Strach M, Grodzicki T, Slowik A. Two novel mutations of the SETX gene and ataxia with oculomotor apraxia type 2. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>2015;<span class="ref-vol">128</span>:44–6.</span> [<a href="/pubmed/25462094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25462094</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.roda.2014.1627">Roda RH, Rinaldi C, Singh R, Schindler AB, Blackstone C. Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage. <span><span class="ref-journal">J Clin Neurosci. </span>2014;<span class="ref-vol">21</span>:1627–31.</span> [<a href="/pmc/articles/PMC4127342/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4127342</span></a>] [<a href="/pubmed/24814856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24814856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.sariki.2016.4056">Sariki SK, Sahu PK, Golla U, Singh V, Azad GK, Tomar RS. Sen1, the homolog of human senataxin, is critical for cell survival through regulation of redox homeostasis, mitochondrial function, and the TOR pathway in Saccharomyces cerevisiae. <span><span class="ref-journal">FEBS J. </span>2016;<span class="ref-vol">283</span>:4056–83.</span> [<a href="/pubmed/27718307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27718307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.sch_ls.2008.495">Sch&#x000f6;ls L, Arning L, Sch&#x000fc;le R, Epplen JT, Timmann D. "Pseudodominant inheritance" of ataxia with ocular apraxia type 2 (AOA2). <span><span class="ref-journal">J Neurol. </span>2008;<span class="ref-vol">255</span>:495–501.</span> [<a href="/pubmed/18350359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18350359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.tazir.2009.77">Tazir M, Ali-Pacha L, M'Zahem A, Delaunoy JP, Fritsch M, Nouioua S, Benhassine T, Assami S, Grid D, Vallat JM, Hamri A, Koenig M. Ataxia with oculomotor apraxia type 2: a clinical and genetic study of 19 patients. <span><span class="ref-journal">J Neurol Sci. </span>2009;<span class="ref-vol">278</span>:77–81.</span> [<a href="/pubmed/19141356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19141356</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa2.REF.z_hlke.2007.207">Z&#x000fc;hlke C, Bernard V, Gillessen-Kaesbach G. Investigation of recessive ataxia loci in patients with young age of onset. <span><span class="ref-journal">Neuropediatrics. </span>2007;<span class="ref-vol">38</span>:207–9.</span> [<a href="/pubmed/18058631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18058631</span></a>]</div></li></ul></div></div><div id="aoa2.Chapter_Notes"><h2 id="_aoa2_Chapter_Notes_">Chapter Notes</h2><div id="aoa2.Acknowledgments"><h3>Acknowledgments</h3><p>The authors wish to thank all patients and their families for their collaboration, as well as all the physicians involved in the clinical study of the families. Genetic studies were supported by funds from the Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia (Portuguese Ministry of Science), the Portuguese Ministry of Health (projects STRDA/C/SAU/277/92 and PECS/C/SAU/219/95), the Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, the Centre National de la Recherche Scientifique, the H&#x000f4;pitaux Universitaires de Strasbourg (PHRC regional), and the GIS-Maladies Rares (SPATAX Research Network. Grant 4MR12FA004DS). MCM had a post-graduate fellowship SFRH/BPD/11502/2002 from Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia (Portuguese Ministry of Science).</p></div><div id="aoa2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 July 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 December 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 March 2009 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically for <i>SETX</i></div></li><li class="half_rhythm"><div>5 March 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>31 May 2005 (mcm) Revision: Sequence analysis clinically available</div></li><li class="half_rhythm"><div>15 November 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>23 June 2004 (mcm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1154</span><span class="label">PMID: <a href="/pubmed/20301333" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301333</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aoa/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/aved/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1154&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1154/?report=reader">PubReader</a></li><li><a href="/books/NBK1154/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1154" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1154" style="display:none" title="Cite this Page"><div class="bk_tt">Moreira MC, Koenig M. Ataxia with Oculomotor Apraxia Type 2. 2004 Nov 15 [Updated 2018 Jul 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1154/pdf/Bookshelf_NBK1154.pdf">PDF version of this page</a> (197K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#aoa2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#aoa2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#aoa2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#aoa2.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#aoa2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#aoa2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#aoa2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#aoa2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#aoa2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#aoa2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#aoa2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=23064[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SETX</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1486488" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1486488" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1486488" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1486488" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301629" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ataxia with Oculomotor Apraxia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ataxia with Oculomotor Apraxia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Coutinho P, Barbot C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23941260" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">SETX mutations are a frequent genetic cause of juvenile and adult onset cerebellar ataxia with neuropathy and elevated serum alpha-fetoprotein.</a><span class="source">[Orphanet J Rare Dis. 2013]</span><div class="brieflinkpop offscreen_noflow">SETX mutations are a frequent genetic cause of juvenile and adult onset cerebellar ataxia with neuropathy and elevated serum alpha-fetoprotein.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nanetti L, Cavalieri S, Pensato V, Erbetta A, Pareyson D, Panzeri M, Zorzi G, Antozzi C, Moroni I, Gellera C, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2013 Aug 14; 8:123. Epub 2013 Aug 14.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19696032" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients.</a><span class="source">[Brain. 2009]</span><div class="brieflinkpop offscreen_noflow">Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Anheim M, Monga B, Fleury M, Charles P, Barbot C, Salih M, Delaunoy JP, Fritsch M, Arning L, Synofzik M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Brain. 2009 Oct; 132(Pt 10):2688-98. Epub 2009 Aug 20.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30778901" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Disruption of Spermatogenesis and Infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2).</a><span class="source">[Cerebellum. 2019]</span><div class="brieflinkpop offscreen_noflow">Disruption of Spermatogenesis and Infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Becherel OJ, Fogel BL, Zeitlin SI, Samaratunga H, Greaney J, Homer H, Lavin MF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cerebellum. 2019 Jun; 18(3):448-456. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16131425" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New autosomal recessive cerebellar ataxias with oculomotor apraxia.</a><span class="source">[Curr Neurol Neurosci Rep. 2005]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New autosomal recessive cerebellar ataxias with oculomotor apraxia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Le Ber I, Brice A, Dürr A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Curr Neurol Neurosci Rep. 2005 Sep; 5(5):411-7. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301333" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301333" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04144d39a66ee2bad9f419">Ataxia with Oculomotor Apraxia Type 2 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Ataxia with Oculomotor Apraxia Type 2 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:00:45-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D429EE041106100000000015B008A&amp;ncbi_session=CE8D429EE04144D1_0347SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1154%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1154&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1154/&amp;ncbi_pagename=Ataxia with Oculomotor Apraxia Type 2 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D429EE04144D1_0347SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>